179 related articles for article (PubMed ID: 27341602)
1. Molecular Triage Trials in Colorectal Cancer.
O'Hara MH; Hamilton SR; O'Dwyer PJ
Cancer J; 2016; 22(3):218-22. PubMed ID: 27341602
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis in Colorectal Cancer: Antibodies.
Chan E
Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
[TBL] [Abstract][Full Text] [Related]
3. The impact of targeted therapy on the treatment of colorectal cancer.
Marshall JL; Hwang J
Oncology (Williston Park); 2005 Nov; 19(13 Suppl 6):19-24. PubMed ID: 16502666
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
5. Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors.
Kircher SM; Nimeiri HS; Benson AB
Cancer J; 2016; 22(3):182-9. PubMed ID: 27341596
[TBL] [Abstract][Full Text] [Related]
6. Aspirin, the new targeted therapy in colorectal cancer.
Fuchs CS
Clin Adv Hematol Oncol; 2014 Mar; 12(3):186-9. PubMed ID: 24927268
[No Abstract] [Full Text] [Related]
7. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.
Stintzing S; Stremitzer S; Sebio A; Lenz HJ
Hematol Oncol Clin North Am; 2015 Feb; 29(1):43-60. PubMed ID: 25475572
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer: how emerging molecular understanding affects treatment decisions.
Sridharan M; Hubbard JM; Grothey A
Oncology (Williston Park); 2014 Feb; 28(2):110-8. PubMed ID: 24701697
[TBL] [Abstract][Full Text] [Related]
10. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
11. K-Ras mutations are changing practice in advanced colorectal cancer.
McNeil C
J Natl Cancer Inst; 2008 Dec; 100(23):1667-9. PubMed ID: 19033564
[No Abstract] [Full Text] [Related]
12. Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies?
Mitry E; Rollot F; Jooste V; Guiu B; Lepage C; Ghiringhelli F; Faivre J; Bouvier AM
Eur J Cancer; 2013 Sep; 49(13):2919-25. PubMed ID: 23642328
[TBL] [Abstract][Full Text] [Related]
13. The next generation of targeted therapy trials in colorectal cancer.
O'Dwyer PJ
Clin Adv Hematol Oncol; 2014 Dec; 12(12):852-4. PubMed ID: 25674843
[No Abstract] [Full Text] [Related]
14. Recent advances in colorectal cancer therapy.
d'Entremont TS; Sun W
Cancer Biol Ther; 2003; 2(1):6-13. PubMed ID: 12673111
[TBL] [Abstract][Full Text] [Related]
15. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
16. Personalized-medicine trials on the rise.
Benowitz S
J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
[No Abstract] [Full Text] [Related]
17. Targeted therapy in first line treatment of RAS wild type colorectal cancer.
Formica V; Roselli M
World J Gastroenterol; 2015 Mar; 21(10):2871-4. PubMed ID: 25780283
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs in refractory colorectal cancer.
Nobili S; Galletta A; Brugia M; Tassi R; Petreni P; Landini I; Mini E
Future Med Chem; 2015 Aug; 7(12):1491-501. PubMed ID: 26293581
[TBL] [Abstract][Full Text] [Related]
19. The role of the PI3K pathway in colorectal cancer.
Papadatos-Pastos D; Rabbie R; Ross P; Sarker D
Crit Rev Oncol Hematol; 2015 Apr; 94(1):18-30. PubMed ID: 25591826
[TBL] [Abstract][Full Text] [Related]
20. A small cog in a big wheel: PIK3CA mutations in colorectal cancer.
Stintzing S; Lenz HJ
J Natl Cancer Inst; 2013 Dec; 105(23):1775-6. PubMed ID: 24231451
[No Abstract] [Full Text] [Related]
[Next] [New Search]
